Newsletter | February 9, 2024

02.09.24 -- Insights From Animals And Evolution


Pricing, Value, And Access To CGTs With The Dedham Group's Jennifer Klarer, M.Sc. Eng.

The Dedham Group's Jennifer Klarer, M.Sc. Eng., joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value of CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time to treatment issues typically experienced at launch. Listen now to their discussion about obtaining adequate investment dollars.


Innovation From Animals And Evolution

Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.


Ensuring Diversity And Accessibility In Neurological Research

The landscape of neurological and rare disorders is as diverse as the human population it affects. Yet, clinical trials for these conditions have not always mirrored this diversity.


Allogeneic Vs. Autologous Cell Therapy: Deciding On Your Product Strategy

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs.

The MAPPs Assay: A Useful Tool For The Assessment Of Immunogenicity

Explore how MAPPs demonstrates promise as a valuable tool for comprehensive immunogenicity assessment in therapeutic protein development, contributing to safer and more effective biologics.

The FDA Race And Ethnicity Diversity Plan

Understand how the DEPICT Act not only underscores the importance of diversity in research but also sets the stage for a more inclusive and comprehensive approach to healthcare development in the U.S.

Overcoming Manufacturing Challenges For Accelerated Drug Development

Expedited development programs require adapting to accelerated development timelines. The challenge is to build a strategy that maintains the integrity, quality, and timeliness of the manufacturing process.

Overcoming Cell Line Development Challenges With Early-Stage Processes

The biopharmaceutical industry is trending toward building process characterization systems and processes early in a project’s life cycle, enabling success for later-stage development.


Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director. 

Connect With Life Science Leader: